Introduction {#S0001}
============

Breast cancer (BC) is the most frequently diagnosed cancer and is the leading cause of cancer-related deaths among women.[@CIT0001] Liver metastasis occurs in 15% of newly diagnosed BC patients and has a survival time of 4--8 months.[@CIT0002] Therefore, identification of biomarkers of BC with liver metastases is urgently needed.

Currently, there is a lack of reliable predictive and prognostic biomarkers that hamper effective implementation of individualised patient stratification essential for tailoring treatment decisions.[@CIT0003] Recent studies demonstrated that premenopausal women have lower survival rates and respond less to conventional chemotherapy compared to the majority of postmenopausal BC. Patient stratification approach utilising menopausal status will result in improved clinical utility of biomarker patterns.[@CIT0004],[@CIT0005] In addition, liquid biopsies have encouraged researchers to develop noninvasive signatures that can be exploited as biomarkers for metastatic evaluation.[@CIT0006]

There is plenty of evidence that demonstrated that platelet activation and platelet-cancer cell interaction are crucial for cancer metastases. Thrombocytosis correlates with a worse prognosis in many cancers, such as gastric, pancreatic, colorectal, ovarian, and endometrial cancer.[@CIT0007]--[@CIT0011] A commonly used measurement of platelet size in clinical practice is mean platelet volume (MPV). MPV is an indicator of platelet activation.[@CIT0012] Alteration of MPV levels in breast, lung, gastric, colon, and ovarian cancer has been reported.[@CIT0013]--[@CIT0016] However, its clinical implication in BC liver metastases has not been investigated.

The current study was to evaluate whether there is a difference in MPV between patients with metastatic BC with liver metastases and those with BC without liver metastases.

Methods {#S0002}
=======

Study Population {#S0002-S2001}
----------------

211 BC patients with synchronous liver metastases and 215 BC patients without metastases at the Harbin Medical University Cancer Hospital between January 2014 and December 2017 were screened for enrolment in the present study by reviewing electronic charts. All BC patients received MRI scanning of head, CT lung screening, abdominal enhanced MRI, and ECT evaluation of skeletal metastases to rule out distant metastases. All BC patients without metastases undergone complete surgical resection. The diagnosis of BC was confirmed by histology. Synchronous liver metastases were defined as a time interval between the diagnosis of the primary BC and development of liver metastases within 6 months. None of the patients had received surgical treatment, radiotherapy or chemotherapy before enrolment. Patient demographics and clinicopathologic data were obtained from the databases in our hospital. The patients with hematological disorders and medical treatment with acetylic salicylic acid were excluded from our study.

The study protocol was approved by the Ethics Committee of the Institutional Ethics Review Board of Harbin Medical University Cancer Hospital (2018-x0352), and a signed informed consent was obtained from each patient. This study was conducted in accordance with the Declaration of Helsinki.

Statistical Analysis {#S0002-S2002}
--------------------

The statistical tests were carried out using SPSS version 25.0 software (SPSS Inc., Chicago, IL, USA). Normally distributed continuous variables between two groups were compared with the independent *t*-test or Mann--Whitney's U-test. Categorical variables were compared with the Chi-square test. All subjects were stratified into quartiles according to their MPV levels. The MPV quartiles were quartile 1 (Q1) (≤7.7 fL), quartile 2 (Q2) (7.8--8.4 fL), quartile 3 (Q3) (8.5--9.3 fL), quartile 4 (Q4) (≥9.4 fL). The odds ratios (ORs) and 95% confidence intervals (95% CIs) for liver metastasis were calculated after adjusting for confounding variables across MPV quartiles using multivariate logistic regression analysis. P \< 0.05 was considered to indicate a statistically significant difference.

Results {#S0003}
=======

We enrolled 426 BC patients in this retrospective study. The median age of patients was 52 years (range: 21--80 years). The baseline clinicopathological characteristics of patients are listed in [Table 1](#T0001){ref-type="table"}. The patients with liver metastases were older and had lower body mass index, haemoglobin, and MPV, and higher lactate dehydrogenase, CEA, and CA153 levels. However, menopausal status, fasting plasma glucose, albumin, creatinine, platelet count, platelet distribution width, and tumor molecular subtype in two groups had no difference.Table 1Baseline Characteristics Of BC PatientsVariablesWith Liver MetastasesWithout Liver Metastases*P* valueN211215Age (years)52.9 (8.8)50.4 (9.8)0.006BMI (kg/m^2^)23.4 (3.4)24.2 (3.0)0.007Menopausal status (Post, %)138 (65.4)134 (62.3)0.234FPG (mmol/L)5.20 (4.90-- 5.83)5.20 (4.90-- 5.60)0.205Albumin (g/L)44.0 (5.3)45.0 (5.3)0.063Creatinine (umol/L)68.0 (18.3)71.2 (15.6)0.053WBC (×10^9^/L)6.2 (2.1)6.1 (1.8)0.423Haemoglobin (g/dL)124.8 (16.1)134.6 (12.2)\<0.001Platelet count (×10^9^/L)239.7 (81.2)235.5 (51.8)0.524MPV (fL)8.2 (1.4)9.1 (1.2)\<0.001PDW (%)16.9 (1.5)16.8 (1.0)0.137Lactate dehydrogenase (U/L)200.0(157.2--286.0)153.0(138.0--172.0)\<0.001CEA (ng/mL)12.8 (2.7--59.7)1.3 (0.9--2.0)\<0.001CA153 (U/mL)81.7 (25.3--287.0)9.8 (7.3--13.4)\<0.001ER (Positive, %)119 (56.4)138 (64.2)0.100PR (Positive, %)115 (54.5)135 (62.8)0.082HER-2 status (Positive, %)76 (36.0)92 (42.8)0.153Tumor molecular subtype Luminal-A121 (57.3)107 (49.8)0.117 Luminal-B49 (23.2)46 (21.4)0.651 HER 2+20 (9.5)32 (14.9)0.088 TNBC21 (10.0)30 (14.0)0.203[^2]

MPV levels were shown using menopausal status and triple-negative breast cancer (TNBC) molecular subtype to stratify the BC patients ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=221976.doc)]{.ul}). There was a difference in MPV in premenopausal non-TNBC patients according to liver metastases status (9.3±1.3 fL vs 7.8±1.3 fL, p \< 0.001) ([[Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=221976.doc)]{.ul}). In postmenopausal non-TNBC patients, compared with the patients with liver metastases, higher MPV levels were observed in patients without liver metastases (9.1±1.0 fL vs 8.3±1.5 fL, p \< 0.001) ([[Figure S3](https://www.dovepress.com/get_supplementary_file.php?f=221976.doc)]{.ul}). In addition, there was a significant difference in MPV in postmenopausal TNBC patients according to liver metastases status (9.3±1.6 fL vs 7.8±1.0 fL, p = 0.003) ([[Figure S3](https://www.dovepress.com/get_supplementary_file.php?f=221976.doc)]{.ul}).

MPV levels were presented using menopausal status and human epidermal growth factor receptor (HER2) positive molecular subtype to stratify the BC patients ([[Figure S4](https://www.dovepress.com/get_supplementary_file.php?f=221976.doc)]{.ul}). Similar to the postmenopausal non-TNBC patterns, there was a difference in MPV in premenopausal non-HER2+ BC patients according to liver metastases status (9.0±1.3 fL vs 8.1±1.3 fL, p \< 0.001) ([[Figure S5](https://www.dovepress.com/get_supplementary_file.php?f=221976.doc)]{.ul}). In postmenopausal HER2+ BC patients, MPV levels were higher in patients without liver metastases compared with those in patients with liver metastases (9.5±1.0 fL vs 7.7±0.5 fL, p = 0.026) ([[Figure S6](https://www.dovepress.com/get_supplementary_file.php?f=221976.doc)]{.ul}). In addition, a notable difference in MPV was found in postmenopausal non-HER2+ BC patients according to liver metastases status (9.1±1.1 fL vs 8.2±1.4 fL, p \< 0.001) ([[Figure S6](https://www.dovepress.com/get_supplementary_file.php?f=221976.doc)]{.ul}).

The platelet indices in BC patients are shown in [Table 2](#T0002){ref-type="table"}. In the group with non-liver metastases, platelet distribution width was significantly associated with tumor N stage. In the group with liver metastases, there were no differences of platelet indices observed in liver tumor nodules, liver tumor size, and extrahepatic involvement.Table 2Platelet Indices In BC PatientsVariablesPLT(×10^9^/L)*P* valueMPV(fL)*P* valuePDW(%)*P* value**Without liver metastases**Tumor T stage0.5440.9850.136 T1+T2235.0 (51.3)9.1 (1.2)16.7 (1.0) T3+T4245.2 (64.4)9.1 (1.3)17.2 (0.7)Tumor N stage0.3210.1150.046 N0234.3 (50.8)9.1 (1.1)16.7 (1.0) N1--3246.1 (60.8)8.7 (1.5)17.2 (0.7)Tumor Size0.8110.7810.198 \<2.5 cm235.0 (50.9)9.1 (1.1)16.7 (1.0) ≥2.5 cm237.1 (55.9)9.0 (1.6)16.9 (1.1)**With liver metastases**Liver Tumor Nodules0.9750.3900.700 \<2239.8 (85.5)8.4 (1.3)16.9 (1.6) ≥2239.8 (85.5)8.2 (1.4)17.0 (1.4)Liver Tumor Size0.3850.0520.069 ≤50 mm241.8 (80.7)8.1 (1.3)16.9 (1.5) \>50 mm228.6 (84.0)8.6 (1.6)17.4 (1.2)Extrahepatic Involvement0.5580.1680.853 Liver only involved241.0 (82.7)8.2 (1.4)16.9 (1.5) Liver + other sites^a^231.3 (70.8)8.6 (1.6)17.0 (1.3)[^3]

The prevalence of liver metastases was calculated by the quartiles of MPV levels ([Figure 1](#F0001){ref-type="fig"}). The prevalence rate of liver metastases in Q1, Q2, Q3, and Q4 was 82.3% (93/113), 50.5% (52/103), 27.0% (30/111), and 36.4% (36/99), respectively. The prevalence rate of liver metastases in Q1 was significantly higher than that in Q2, Q3 and Q4. The results indicated that the prevalence of liver metastases reduced as MPV quartiles increased (p \< 0.001).Figure 1The prevalence rate of liver metastases (%) in BC patients according to MPV quartiles.**Notes:** [Figure 1](#F0001){ref-type="fig"} shows the association between MPV levels and prevalence rate of liver metastases in BC patients (%). Participants were stratified into quartiles according to their MPV levels. The prevalence of liver metastases is calculated by the quartiles of MPV levels.

The risks of liver metastases according to MPV quartiles are shown in [Table 3](#T0003){ref-type="table"}. After adjusting for age, body mass index, menopausal status, fasting plasma glucose, albumin, haemoglobin, creatinine, and white blood cell, the prevalence risk of liver metastases for the highest quartile of MPV was 1.757 (1.024--3.015).Table 3The Risks Of Liver Metastases In BC Patients According To MPV QuartilesCasesControlsOR (95% CI)p-valueQ1 (≤7.8 fL)93201 (reference)Q2 (7.9--8.5 fL)52510.267 (0.134--0.530)\<0.001Q3 (8.6--9.4 fL)30810.072 (0.034--0.152)\<0.001Q4 (≥9.5 fL)36630.137 (0.066--0.281)\<0.001[^4][^5]

Discussion {#S0004}
==========

Our study demonstrated that BC patients with liver metastases had lower MPV levels compared to BC patients without metastases. Furthermore, MPV was independently associated with the presence of liver metastases.

Despite the best current medical and surgical treatment, the overall prognosis of BC patients with liver metastases remains poor. Therefore, it is of great importance to identify novel biomarkers for treatment. The interaction of cancer cells with platelets leads to platelet activation, and, on the other hand, platelet activation is strongly instrumental to the pro-carcinogenic and pro-metastatic activities of platelets.[@CIT0017] In breast cancer, platelet-derived growth factor (PDGF) expression is associated with biological aggressiveness via NFkappaB signaling pathway.[@CIT0018],[@CIT0019] Platelet-derived lysophosphatidic acid accelerates osteolytic bone metastases.[@CIT0020] In addition, platelet releasate increases BC cell proliferation through VEGF-integrin cooperative signaling.[@CIT0021] A recent study found that ticagrelor, a P2Y12 inhibitor, could reduce tumor growth and metastasis in human and murine breast cancer cells.[@CIT0022]

In agreement with the studies above, our study confirmed the important role of activated platelets in BC. Moreover, our study can form the basis for further mechanistic studies and ultimately aid in patient-tailored selection of therapeutic strategies. Monitoring the changes of MPV maybe contribute to early detection of liver metastases in BC patients. In addition, patient stratification approach utilising menopausal status, MPV levels, and molecular subtype may be helpful for metastatic evaluation. In addition, the results underlined the importance of activated platelets involved in liver metastases and pointed out the need for further mechanistic research.

The mechanisms underlying the association between MPV and survival in BC patients with liver metastases remain unclear. Cancer changes platelet behavior by directly inducing tumor-platelet aggregates, triggering platelet granule and extracellular vesicle release, altering platelet phenotype and platelet RNA profiles, and enhancing thrombopoiesis.[@CIT0023] MPV is an early indicator of activated platelets. Strong evidence revealed that larger platelets are more metabolically and enzymatically active than smaller platelets. Direct or indirect interaction of platelets induces cancer cell plasticity and enhances survival and extravasation of circulating cancer cells during dissemination.[@CIT0024] Platelets physically and functionally interact with tumor cells through surface receptors including integrins. The main role of two platelet integrins, α6β1 and αIIbβ3, was proposed to participate in tumor metastasis via platelet adhesion and aggregation at sites of vascular injury.[@CIT0025] The secretory factors released by activated platelets promote chemokines, proteolytic enzymes and microparticles within the microenvironment and accelerate tumor cell invasion.[@CIT0026] In addition, aspirin and clopidogrel inhibit the expression of α-granule-stored proteins that are involved in heterotypic interactions between platelets/leukocytes and the endothelium.[@CIT0027]

In accord with our results, Tuncel et al reported that increased MPV was a prognostic factor for metastatic colorectal cancer patients treated with bevacizumab-combined chemotherapy.[@CIT0028] Gu et al found that high pre-treatment MPV levels in invasive breast cancer patients were associated with worse clinicopathologic features.[@CIT0029] Lian et al observed that high baseline MPV levels were associated with increased metastases.[@CIT0030] These findings are also consistent with the current knowledge that anti-platelet is considered to be a part of cancer adjuvant therapy.[@CIT0031]

There are several limitations of this study. First, the current study was a retrospective analysis with a limited number of patients. Thus, a more thorough investigation in a larger series of patients is necessary to confirm the results. Second, the mechanisms underlying the involvement of MPV in BC patients with liver metastases remain unclear. Further experiments which are designed to identify the precise mechanism are warranted. Third, the patients were composed of only Chinese. External validation is still needed to confirm whether our results can be generalized to a new patient population.

Outlook {#S0004-S2001}
-------

Breast cancer is a heterogeneous disease. Different molecular subtypes of breast cancer can change longitudinally during treatment resulting in treatment failures and requiring different therapeutic approaches.[@CIT0032] The subclassification of breast cancers will allow physicians to tailor effective treatments to target this heterogeneity. DNA sequencing, mRNA micro-arrays, next-generation sequencing, and an array of proteomics assays have allowed profiling of large numbers of tumors based on mutational profiles and aberrant gene and protein expression.[@CIT0033] Multi-omic approach may discover a unique molecular signature of the TNBC subtype and could be of great clinical utility for development of predictive diagnosis and targeted treatments.[@CIT0034],[@CIT0035]

In summary, MPV is reduced in BC patients with liver metastases compared with BC patients without metastases. Moreover, MPV is independently associated with the presence of liver metastases. Further studies are needed.
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